新加坡HLA相关基因型指导处方的实施
本文描述新加坡实施HLA相关基因型指导处方的情况。涉及HLA-B*15:02与卡马西平所致SJS/TEN、HLA-B*58:01与别嘌醇所致严重皮肤不良反应、HLA-B*57:01与阿巴卡韦超敏反应。卡马西平的成功显示可减少DHS和医疗成本,但别嘌醇和阿巴卡韦的基因型指导处方在全人群实施并不均具成本效果。
要点
- HLA-B*15:02与卡马西平所致SJS/TEN相关,基因型指导处方可减少DHS。
- HLA-B*58:01与别嘌醇严重皮肤不良反应风险增加相关。
- HLA-B*57:01与阿巴卡韦超敏反应风险增加相关。
核心结论
- HLA相关基因型指导处方有潜力减少DHS发生率并降低医疗成本,卡马西平已显示成功。
- 并非所有基因型指导处方在全人群实施均具成本效果,别嘌醇和阿巴卡韦的本地研究已表明这一点。
- 成本效果可能随新数据(如等位基因频率、检测成本、药品价格、基因分型方法)变化,应定期和本地评估。
- 将先发药物基因组学面板检测纳入常规临床护理可能改变成本效果阈值,并有望通过精准医学进一步优化药物治疗。
研究设计与样本
- 本文为描述新加坡HLA相关基因型指导处方实施的综述性文章,未报告系统检索范围。
主要发现
- 新加坡存在HLA相关DHS的流行,涉及HLA-B*15:02、HLA-B*58:01和HLA-B*57:01等位基因。
- 卡马西平的基因型指导处方已显示成功,可减少DHS和医疗成本。
- 别嘌醇和阿巴卡韦的基因型指导处方在全人群实施并不均具成本效果。
临床怎么用
- 临床可依据HLA-B*15:02指导卡马西平处方以减少SJS/TEN风险。
- 别嘌醇和阿巴卡韦的基因型指导处方需结合本地成本效果评估实施。
- 考虑将先发药物基因组学面板检测纳入常规临床护理以优化药物治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To describe the implementation of human leukocyte antigen (HLA)-related genotype-guided prescribing in Singapore. SUMMARY: Various HLA alleles have been implicated in drug hypersensitivity syndromes (DHS). These include HLA-B*15:02, which has been associated with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis, HLA-B*58:01, which has been associated with increased risk of severe cutaneous adverse reactions with allopurinol use, and HLA-B*57:01, which has been associated with increased risk of hypersensitivity reactions with abacavir use. Integrating pharmacogenomics into patient care through genotype-guided prescribing potentially optimizes use of these drugs by reducing DHS-related and healthcare costs. We describe the prevalence of HLA-related DHS in Singapore, the cost-effectiveness of genotype-guided prescribing, and local policies and guidelines, as well as the impact of genotype-guided prescribing where available. CONCLUSION: HLA-related genotype-guided prescribing has the potential to reduce the incidence of DHS and decrease healthcare costs, as seen in the success with carbamazepine. However, not all genotype-guided prescribing is cost-effective when implemented across the population, as was evident from local studies for allopurinol and abacavir. The cost-effectiveness of such measures may change over time with new data (eg, allele frequencies, test costs, drug prices, genotyping approach) and should be evaluated periodically and locally. Implementation of preemptive pharmacogenomics panel testing as part of routine clinical care may shift the threshold for cost-effectiveness and brings promise of further optimization of pharmacotherapy through precision medicine.
引用
- Chua HM, Limenta M, Ng CYL, et al. Implementation of HLA-related genotype-guided prescribing in Singapore. Am J Health Syst Pharm. 2025. PMID: 39405418. doi:10.1093/ajhp/zxae294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。